Financial Insights’s DexCom DXCM Stock Holding History

Financial Insights’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,260	Closed	-$219K	–	132
2025 Q3	$219K	Buy	3,260 +203	+7%	+$16.1K	0.07%	131
2025 Q2	$267K	Buy	+3,057	New	+$240K	0.1%	102
2024 Q3	–	Sell	-2,138	Closed	-$242K	–	152
2024 Q2	$242K	Buy	+2,138	New	+$270K	0.07%	145

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Financial Insights's DXCM Position: Q4 2025 in Review

Financial Insights sold out of DexCom (DXCM) in Q4 2025, closing a stake of 3,260 shares — an estimated $219K sold.

Financial Insights first reported a position in DXCM in Q2 2024 and held it in 3 quarters. The position peaked at $267K in Q2 2025. 922 funds tracked by Wall St. Rank hold DXCM as of Q4 2025.

Financial Insights reported no remaining DexCom position as of Q4 2025 after selling out during the quarter.
Financial Insights sold 3,260 DexCom shares in Q4 2025, an estimated $219K.
Financial Insights first reported a position in DexCom in Q2 2024 and held it in 3 quarters.
Financial Insights's DexCom position peaked at $267K in Q2 2025.
922 funds tracked by Wall St. Rank held DexCom as of Q4 2025.

Based on Financial Insights's 13F filing for Q4 2025, filed 1 Apr 2026.